Lipocine Inc (LPCN)
4.84
+0.16
(+3.42%)
USD |
NASDAQ |
Dec 20, 16:00
4.87
+0.03
(+0.62%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 25.88M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 62.42% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 5.385 |
| Price to Book Value | 1.354 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 98.27% |
Profile
| Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology. |
| URL | https://www.lipocine.com |
| Investor Relations URL | https://ir.lipocine.com/ |
| HQ State/Province | Utah |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Mar. 07, 2025 (est.) |
| Last Earnings Release | Nov. 07, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology. |
| URL | https://www.lipocine.com |
| Investor Relations URL | https://ir.lipocine.com/ |
| HQ State/Province | Utah |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Mar. 07, 2025 (est.) |
| Last Earnings Release | Nov. 07, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |